Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALX ONCOLOGY HOLDINGS INCALXO · Entity 6040 | Director | January 20, 2026 | January 21, 2026 |
| IGM Biosciences, Inc.IGMS · Entity 76422 | CHIEF MEDICAL OFFICER | September 13, 2024 | September 17, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALX ONCOLOGY HOLDINGS INC
Report date January 20, 2026 · Filed January 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.32 · Expires 2036-01-19 | Direct | 40,400 |
Reported balance
After 2026-01-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-20 · Grant · Acquired 40,400 · Balance 40,400 F1: Shares subject to the option vest in 12 equal monthly installments beginning on February 20, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares subject to the option vest in 12 equal monthly installments beginning on February 20, 2026.
IGM Biosciences, Inc.
Report date September 13, 2024 · Filed September 17, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 154,331 |
Reported balance
After 2024-09-13 transaction · row 1
1 source rowRow 1 · 2024-09-13 · Sale · Disposed 1,487 · Balance 154,331 F1: These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F2: This transaction was executed in multiple trades at prices ranging from $11.20 to $11.795. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units.
F2: This transaction was executed in multiple trades at prices ranging from $11.20 to $11.795. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Forty Seven, Inc.
Report date April 07, 2020 · Filed April 07, 2020
Section 16 reporting ended · disclosed 2020-04-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-04-07 transaction · row 1
1 source rowRow 1 · 2020-04-07 · Disposition to issuer · Disposed 3,906 · Balance 0 F1: Disposed of pursuant to an agreement and plan of merger by and between the Issuer, Gilead Sciences, Inc. ("Gilead") and Toro Merger Sub, Inc. ("Purchaser") (the "Merger") in exchange for $95.50 per share, net to the holder in cash, without interest and subject to any withholding of taxes, upon the terms and subject to the conditions described in the Offer to Purchase dated March 10, 2020 (together with any amendments or supplements thereto, the "Offer to Purchase") and in the accompanying Letter of Transmittal (together with any amendments or supplements thereto), which are annexed to and filed with the Schedule TO as Exhibits (a)(1)(A) and (a)(1)(B), respectively. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.02 · Expires 2026-02-25 | Direct | 0 |
Reported balance
After 2020-04-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-04-07 · Disposition to issuer · Disposed 58,114 · Balance 0 F2: This option was canceled in the Merger in exchange for a cash payment of $5,432,787.29, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.88 · Expires 2027-08-14 | Direct | 0 |
Reported balance
After 2020-04-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-04-07 · Disposition to issuer · Disposed 4,570 · Balance 0 F3: This option, which provided for vesting over a four-year period as follows: 1/48th of the shares subject to the option vest in a series of 48 successive equal monthly installments beginning August 15, 2017, subject to the Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $414,121.98, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.27 · Expires 2027-11-27 | Direct | 0 |
Reported balance
After 2020-04-07 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-04-07 · Disposition to issuer · Disposed 70,398 · Balance 0 F4: This option, which provided for vesting over a four-year period as follows: 1/48th of the shares subject to the option vest in a series of 48 successive equal monthly installments beginning November 8, 2017, subject to Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $6,352,011.54, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.76 · Expires 2028-04-26 | Direct | 0 |
Reported balance
After 2020-04-07 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-04-07 · Disposition to issuer · Disposed 44,710 · Balance 0 F5: This option, which provided for vesting over a four-year period as follows: 1/48th of the shares subject to the option vest in a series of 48 successive equal monthly installments beginning March 1, 2019, subject to Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $3,878,257.18, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.75 · Expires 2029-12-12 | Direct | 0 |
Reported balance
After 2020-04-07 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-04-07 · Disposition to issuer · Disposed 113,153 · Balance 0 F6: This option, which provided for vesting over a four-year period as follows: 1/48th of the shares subject to the option vest in a series of 48 successive equal monthly installments beginning December 13, 2019, subject to Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $6,760,891.75, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to an agreement and plan of merger by and between the Issuer, Gilead Sciences, Inc. ("Gilead") and Toro Merger Sub, Inc. ("Purchaser") (the "Merger") in exchange for $95.50 per share, net to the holder in cash, without interest and subject to any withholding of taxes, upon the terms and subject to the conditions described in the Offer to Purchase dated March 10, 2020 (together with any amendments or supplements thereto, the "Offer to Purchase") and in the accompanying Letter of Transmittal (together with any amendments or supplements thereto), which are annexed to and filed with the Schedule TO as Exhibits (a)(1)(A) and (a)(1)(B), respectively.
F2: This option was canceled in the Merger in exchange for a cash payment of $5,432,787.29, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option.
F3: This option, which provided for vesting over a four-year period as follows: 1/48th of the shares subject to the option vest in a series of 48 successive equal monthly installments beginning August 15, 2017, subject to the Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $414,121.98, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option.
F4: This option, which provided for vesting over a four-year period as follows: 1/48th of the shares subject to the option vest in a series of 48 successive equal monthly installments beginning November 8, 2017, subject to Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $6,352,011.54, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option.
F5: This option, which provided for vesting over a four-year period as follows: 1/48th of the shares subject to the option vest in a series of 48 successive equal monthly installments beginning March 1, 2019, subject to Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $3,878,257.18, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option.
F6: This option, which provided for vesting over a four-year period as follows: 1/48th of the shares subject to the option vest in a series of 48 successive equal monthly installments beginning December 13, 2019, subject to Reporting Person's continuous service as of each such date, was accelerated and canceled in the Merger in exchange for a cash payment of $6,760,891.75, representing the difference between the market value of the common stock underlying the option on the effective date of the Merger ($95.50 per share) and the exercise price applicable to each share of common stock underlying the option, which difference is multiplied by the total number of shares of common stock subject to the option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 09, 2019 Filed Dec 10, 2019 21:53 UTC | Forty Seven, Inc. FTSV · Entity 16035 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $2.02 | $0.00 |
DisclosureSEC source: 0001209191-19-059961 · doc4.xml · derivative · entry 3 Takimoto Chris H · CIK 0001743780 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,741 Underlying: Common Stock · 10,000 shares Expires 2026-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4th of the shares subject to the option vested one year after February 8, 2016 and 1/48th of the shares subject to the option vest monthly thereafter, subject to Reporting Person's continuous service as of each such date. The shares subject to this option may be exercised prior to vesting, subject to Issuer's right to repurchase. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 21:53 UTC | Forty Seven, Inc. FTSV · Entity 16035 | SaleCommon Stock | 10,000 | $30.00 | $300,000.00 |
DisclosureSEC source: 0001209191-19-059961 · doc4.xml · nonDerivative · entry 2 Takimoto Chris H · CIK 0001743780 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in this Form 4 was effected pursuant to a 10b5-1 trading plan. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 21:53 UTC | Forty Seven, Inc. FTSV · Entity 16035 | Exercise / conversionCommon Stock | 10,000 | $2.02 | $20,150.00 |
DisclosureSEC source: 0001209191-19-059961 · doc4.xml · nonDerivative · entry 1 Takimoto Chris H · CIK 0001743780 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 09, 2019 Filed Dec 11, 2019 21:57 UTC | Forty Seven, Inc. FTSV · Entity 16035 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $2.02 | $0.00 |
DisclosureSEC source: 0001209191-19-060143 · doc4.xml · derivative · entry 3 Takimoto Chris H · CIK 0001743780 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,741 Underlying: Common Stock · 10,000 shares Expires 2026-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4th of the shares subject to the option vested one year after February 8, 2016 and 1/48th of the shares subject to the option vest monthly thereafter, subject to Reporting Person's continuous service as of each such date. The shares subject to this option may be exercised prior to vesting, subject to Issuer's right to repurchase. Read SEC document |
| August 16, 2019 Filed Aug 21, 2019 11:37 UTC | Forty Seven, Inc. FTSV · Entity 16035 | SaleCommon Stock | 663 | $6.36 | $4,215.75 |
DisclosureSEC source: 0001209191-19-046934 · doc4.xml · nonDerivative · entry 1 Takimoto Chris H · CIK 0001743780 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in this Form 4 was effected pursuant to a 10b5-1 trading plan. F2 · shares: Reflects shares acquired under the Forty Seven, Inc. 2018 Employee Stock Purchase Plan on August 15, 2019. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.28 to $6.47, inclusive. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth this footnote. Read SEC document |
| May 03, 2019 Filed May 7, 2019 19:33 UTC | Forty Seven, Inc. FTSV · Entity 16035 | Exercise / conversionStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $2.02 | $0.00 |
DisclosureSEC source: 0001209191-19-028110 · doc4.xml · derivative · entry 3 Takimoto Chris H · CIK 0001743780 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,741 Underlying: Common Stock · 8,000 shares Expires 2026-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4th of the shares subject to the option vested one year after February 8, 2016 and 1/48th of the shares subject to the option vest monthly thereafter, subject to Reporting Person's continuous service as of each such date. The shares subject to this option may be exercised prior to vesting, subject to Issuer's right to repurchase. Read SEC document |
| May 03, 2019 Filed May 7, 2019 19:33 UTC | Forty Seven, Inc. FTSV · Entity 16035 | SaleCommon Stock | 8,000 | $17.99 | $143,951.20 |
DisclosureSEC source: 0001209191-19-028110 · doc4.xml · nonDerivative · entry 2 Takimoto Chris H · CIK 0001743780 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in this Form 4 was effected pursuant to a 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.62 to $18.33, inclusive. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth this footnote. Read SEC document |
| May 03, 2019 Filed May 7, 2019 19:33 UTC | Forty Seven, Inc. FTSV · Entity 16035 | Exercise / conversionCommon Stock | 8,000 | $2.02 | $16,120.00 |
DisclosureSEC source: 0001209191-19-028110 · doc4.xml · nonDerivative · entry 1 Takimoto Chris H · CIK 0001743780 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 04, 2019 Filed Apr 8, 2019 19:20 UTC | Forty Seven, Inc. FTSV · Entity 16035 | SaleCommon Stock | 8,000 | $16.39 | $131,104.80 |
DisclosureSEC source: 0001209191-19-024045 · doc4.xml · nonDerivative · entry 2 Takimoto Chris H · CIK 0001743780 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in this Form 4 was effected pursuant to a 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.09 to $16.70, inclusive. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth this footnote. Read SEC document |
| April 04, 2019 Filed Apr 8, 2019 19:20 UTC | Forty Seven, Inc. FTSV · Entity 16035 | Exercise / conversionCommon Stock | 8,000 | $2.02 | $16,120.00 |
DisclosureSEC source: 0001209191-19-024045 · doc4.xml · nonDerivative · entry 1 Takimoto Chris H · CIK 0001743780 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 20:55 UTC | Forty Seven, Inc. FTSV · Entity 16035 | Exercise / conversionStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $2.02 | $0.00 |
DisclosureSEC source: 0001209191-19-017588 · doc4.xml · derivative · entry 3 Takimoto Chris H · CIK 0001743780 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,741 Underlying: Common Stock · 8,000 shares Expires 2026-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4th of the shares subject to the option vested one year after February 8, 2016 and 1/48th of the shares subject to the option vest monthly thereafter, subject to Reporting Person's continuous service as of each such date. The shares subject to this option may be exercised prior to vesting, subject to Issuer's right to repurchase. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 20:55 UTC | Forty Seven, Inc. FTSV · Entity 16035 | SaleCommon Stock | 8,000 | $16.94 | $135,550.40 |
DisclosureSEC source: 0001209191-19-017588 · doc4.xml · nonDerivative · entry 2 Takimoto Chris H · CIK 0001743780 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in this Form 4 was effected pursuant to a 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.50 to $17.30, inclusive. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth this footnote. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 20:55 UTC | Forty Seven, Inc. FTSV · Entity 16035 | Exercise / conversionCommon Stock | 8,000 | $2.02 | $16,120.00 |
DisclosureSEC source: 0001209191-19-017588 · doc4.xml · nonDerivative · entry 1 Takimoto Chris H · CIK 0001743780 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 04, 2019 Filed Apr 8, 2019 19:20 UTC | Forty Seven, Inc. FTSV · Entity 16035 | Exercise / conversionStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $2.02 | $0.00 |
DisclosureSEC source: 0001209191-19-024045 · doc4.xml · derivative · entry 3 Takimoto Chris H · CIK 0001743780 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,741 Underlying: Common Stock · 8,000 shares Expires 2026-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4th of the shares subject to the option vested one year after February 8, 2016 and 1/48th of the shares subject to the option vest monthly thereafter, subject to Reporting Person's continuous service as of each such date. The shares subject to this option may be exercised prior to vesting, subject to Issuer's right to repurchase. Read SEC document |
| February 19, 2019 Filed Feb 21, 2019 19:45 UTC | Forty Seven, Inc. FTSV · Entity 16035 | SaleCommon Stock | 2,500 | $15.05 | $37,621.25 |
DisclosureSEC source: 0001209191-19-012322 · doc4.xml · nonDerivative · entry 1 Takimoto Chris H · CIK 0001743780 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in this Form 4 was effected pursuant to a 10b5-1 trading plan. F2 · shares: Reflects shares acquired under the Forty Seven, Inc. 2018 Employee Stock Purchase Plan on February 15, 2019. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.91 to $15.55, inclusive. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth this footnote. Read SEC document |
| February 04, 2019 Filed Feb 5, 2019 19:02 UTC | Forty Seven, Inc. FTSV · Entity 16035 | Exercise / conversionStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $2.02 | $0.00 |
DisclosureSEC source: 0001209191-19-007526 · doc4.xml · derivative · entry 3 Takimoto Chris H · CIK 0001743780 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,741 Underlying: Common Stock · 8,000 shares Expires 2026-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4th of the shares subject to the option vested one year after February 8, 2016 and 1/48th of the shares subject to the option vest monthly thereafter, subject to Reporting Person's continuous service as of each such date. The shares subject to this option may be exercised prior to vesting, subject to Issuer's right to repurchase. Read SEC document |
| February 04, 2019 Filed Feb 5, 2019 19:02 UTC | Forty Seven, Inc. FTSV · Entity 16035 | SaleCommon Stock | 8,000 | $14.86 | $118,873.60 |
DisclosureSEC source: 0001209191-19-007526 · doc4.xml · nonDerivative · entry 2 Takimoto Chris H · CIK 0001743780 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in this Form 4 was effected pursuant to a 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.49 to $15.15, inclusive. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth this footnote. Read SEC document |
| February 04, 2019 Filed Feb 5, 2019 19:02 UTC | Forty Seven, Inc. FTSV · Entity 16035 | Exercise / conversionCommon Stock | 8,000 | $2.02 | $16,120.00 |
DisclosureSEC source: 0001209191-19-007526 · doc4.xml · nonDerivative · entry 1 Takimoto Chris H · CIK 0001743780 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 04, 2019 Filed Jan 8, 2019 20:17 UTC | Forty Seven, Inc. FTSV · Entity 16035 | Exercise / conversionStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $2.02 | $0.00 |
DisclosureSEC source: 0001209191-19-002922 · doc4.xml · derivative · entry 3 Takimoto Chris H · CIK 0001743780 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,741 Underlying: Common Stock · 8,000 shares Expires 2026-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4th of the shares subject to the option vested one year after February 8, 2016 and 1/48th of the shares subject to the option vest monthly thereafter, subject to Reporting Person's continuous service as of each such date. The shares subject to this option may be exercised prior to vesting, subject to Issuer's right to repurchase. Read SEC document |
| January 04, 2019 Filed Jan 8, 2019 20:17 UTC | Forty Seven, Inc. FTSV · Entity 16035 | SaleCommon Stock | 8,000 | $15.55 | $124,362.40 |
DisclosureSEC source: 0001209191-19-002922 · doc4.xml · nonDerivative · entry 2 Takimoto Chris H · CIK 0001743780 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in this Form 4 was effected pursuant to a 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.10 to $16.02, inclusive. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth this footnote. Read SEC document |
| January 04, 2019 Filed Jan 8, 2019 20:17 UTC | Forty Seven, Inc. FTSV · Entity 16035 | Exercise / conversionCommon Stock | 8,000 | $2.02 | $16,120.00 |
DisclosureSEC source: 0001209191-19-002922 · doc4.xml · nonDerivative · entry 1 Takimoto Chris H · CIK 0001743780 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.